12月2日，一辆承载着进口冷冻马肉的运输车辆在包头海关的全程保障与高效服务下，自蒙古国顺 利抵达满都拉口岸并快速完成通关验放。此次进口业务的顺利开展，为促进区域冷链物流发展和高水平 开放注入了稳定动能。 严把单证审核与检验检疫关，强化一线人员专业技能培训，建立以检疫审批、证书核验、抽样送检 为核心的全链条监管机制，确保进口肉类完全符合我国安全标准。 "此次冷冻马肉高效通关，是包头海关持续优化口岸营商环境、支持特色产品进口的一次成功实 践。下一步，我们将继续推进监管模式创新与服务流程优化，助力更多优质产品快速进口，服务自治区 外向型经济高质量发展。"包头海关监管一科科长刘海说道。 据悉，本次冷冻马肉进口为满都拉口岸开关以来第二次开展该类业务，将进一步丰富口岸进口商品 结构，拓展中蒙贸易合作新空间。 "海关主动送政策上门，为我们安排专员解读冷冻肉类准入政策，全程指导完善质量安全管理体 系，帮助我们快速适应进口监管要求，真正实现了高效通关、安心进口。"满都拉进口肉类指定监管场 地负责人李浩说。 实施"预约通关、即到即查"便利模式，指导企业提前完成冷链仓储与监控设备调试，开展场地与设 施合规性审查，确保全程温控数据可 ...

Core Insights - The Suzhou Free Trade Zone has initiated a pilot program for optimizing warehousing resources among group pharmaceutical enterprises, aiming to innovate regulatory models and stimulate high-quality development in the pharmaceutical industry [1][2] Group 1: Pilot Program Details - The pilot program is a collaboration between the Suzhou Industrial Park Market Supervision Bureau and the Jiangsu Provincial Drug Administration, focusing on legal frameworks, policy boundaries, and implementation pathways for group pharmaceutical enterprises [1] - The program allows pharmaceutical production and wholesale enterprises within the same group to share or integrate warehousing facilities, provided they meet compliance conditions, breaking down previous operational silos [1] - A unified standard for warehousing management has been established, ensuring compliance with the Drug Administration Law and related regulations, with companies being held accountable for drug quality and safety [1] Group 2: Initial Outcomes - Two companies have already qualified for the pilot, demonstrating initial success in optimizing internal assets, reducing redundant warehousing construction, and significantly lowering fixed asset investments and logistics management costs [1] - The internal flow of pharmaceuticals has been streamlined, enhancing logistics efficiency and promoting a more intensive and lean development direction for the pharmaceutical industry [1] Group 3: Future Directions - The pilot represents a significant breakthrough in regulatory innovation for the pharmaceutical sector, providing a "Suzhou solution" to reconcile industry development with regulatory practices [2] - The market supervision bureau plans to conduct one-on-one follow-up guidance for pilot enterprises to address challenges in policy implementation [2]